---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-097135"
form_type: "8-K"
ticker: "COR"
cik: "0001140859"
company_name: "Cencora, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:11:28.962375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cencora raises FY2024 adjusted EPS guidance to $13.60-$13.70; extends Evernorth supply deal through 2029

## Summary
- Adjusted diluted EPS for FY2024 raised to $13.60-$13.70 from prior $13.55-$13.65.
- FY2025 adjusted operating income and EPS growth expected at bottom of long-term targets (5-8% and 8-12%).
- FY2025 headwinds include COVID products and potential June 2025 loss of an oncology customer after its pending acquisition.
- Extended pharmaceutical supply agreement with Evernorth Health Services for three additional years through September 2029.

## SEC filing metadata
- accession: 0001104659-24-097135
- form_type: 8-K
- ticker: COR
- cik: 0001140859
- company_name: Cencora, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1140859/000110465924097135/0001104659-24-097135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1140859/000110465924097135/tm2423361d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-097135
- JSON: https://secwatch.observer/filing/0001104659-24-097135.json
- Plain text: https://secwatch.observer/filing/0001104659-24-097135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.